Business
Publication on sulforaphane in COVID-19
Publication on sulforaphane in COVID-19.
About this update from Theracryf Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5753U\n Evgen Pharma PLC\n 07 April 2021\n \n \n \n \n Evgen Pharma Plc\n \n \n (\"Evgen\" or \"the Company\")\n \n \n \n \n \n Publication on sulforaphane in COVID-19\n \n \n Recent pre-print publication shows in vitro and in vivo antiviral activity of sulforaphane against the virus responsible for COVID-19\n \n \n \n \n \n Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome notes a recent pre-print publication from Johns Hopkins University, USA1. The publication demonstrates that sulforaphane, the active ingredient in SFX-01, prevents virus-induced cell death in vitro induced by several variants of the SARS-CoV-2 virus and another coronavirus.\n \n \n \n \n \n The paper goes on to demonstrate that the inhibition of SARS-CoV-2 cytotoxicity by sulforaphane occurs both when cells are pre-treated with sulforaphane and when sulforaphane is administered 24 hours after viral inoculation. The work also shows that sulforaphane acts synergistically with the antiviral drug remdesivir. The authors further established that the effects of sulforaphane, administered orally, were observed in vivo in a mouse model infected with the SARS-CoV-2 virus where reduction in both viral load and lung pathology were observed. The data have been published before peer review given the urgency of the current pandemic. \n \n \n \n \n \n Evgen's SFX-01 is a druggable, clinical grade medicine currently at the clinical trial stage containing synthetic sulforaphane in a stable complex.\n \n \n \n \n \n \n Dr Huw Jones CEO of Evgen commented: \n \n \n \"We are pleased to note these findings from Johns Hopkins University. If the data continue to demonstrate efficacy after peer review, they underpin and support the hypothesis we are testing with the University of Dundee in the STAR COVID-19 clinical study. We anticipate receiving the outcome of the interim analysis of the first 100 patients completing the study during this second quarter of 2021.\"\n \n \n \n \n \n \n \n 1\n \n \n Odronez et al, https://www.biorxiv.org/content/10.1101/2021.03.25.437060v1\n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n \n \n Evgen Pharma\n \n plc \n www.evgen.com\n \n \n \n \n \...